From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

Ruxolitinib Plus Azacitidine Improves Survival, Bone Marrow Fibrosis in Myelofibrosis

Adding azacitidine to ruxolitinib led to an “encouraging” spleen and bone marrow fibrosis response rate in patients with myelofibrosis (MF), compared with previous experience...

Evaluating Twice-Yearly Denosumab for Transfusion-Dependent, Thalassemia-Induced Osteoporosis

Treatment with twice-yearly denosumab improved spinal bone mineral density (BMD) compared with placebo in patients with transfusion-dependent thalassemia (TDT)–induced osteoporosis, according to results of...
WIB_icon

Pre-emptive Rituximab Prevents Long-Term Relapses in Immune-Mediated TTP

Patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who have persistent, severe ADAMTS13 deficiency have a high likelihood of relapse, but pre-emptive treatment with rituximab...
WIB_icon

MRD Negativity Measured Via Next-Generation Sequencing Predicts Long-Term Survival in Myeloma

Measuring minimal residual disease (MRD) status using next-generation sequencing (NGS) represented a prognostic biomarker for survival in patients with multiple myeloma (MM), according to...
WIB_icon

Next-Generation Sequencing MRD Assessment Valuable Tool in AML Management

Assessing minimal residual disease (MRD) using next-generation sequencing (NGS) in patients with acute myeloid leukemia (AML) prior to undergoing allogeneic hematopoietic cell transplantation (alloHCT)...
WIB_icon

Risk of Thrombosis in Patients With Cancer and Implanted Ports

Although patients with solid-tumor cancers and implanted ports have a high risk for venous thromboembolism (VTE), guidelines advise against routine thromboprophylaxis, given the wide...
WIB_icon

Examining Hospice Use Among Transfusion-Dependent Patients With Leukemia

Since 2001, more patients with leukemia are receiving hospice services, which has been associated with improved quality of life, according to an analysis published...
WIB_icon

Mapping Silent Cerebral Infarcts in Children With Sickle Cell Anemia

Children with sickle cell anemia (SCA) are at risk of developing cerebral ischemia, including a high prevalence of silent cerebral infarcts (SCI), which can...

Carfilzomib Benefits Outweigh Potential for Cardiac Toxicity in Relapsed/Refractory Myeloma

While clinical trials of the proteasome inhibitor carfilzomib for the treatment of multiple myeloma (MM) showed varying incidence rates of cardiovascular adverse events (AEs),...

Can Cytarabine Prevent Progression to Myeloid Leukemia in Children With Down Syndrome and Transient...

In pediatric patients with Down syndrome (DS) and transient myeloproliferative disorder (TMD), treatment with low-dose cytarabine lowered early mortality risk, compared with historical controls,...
Advertisement

Current Issue

November 2018, Volume 4, Issue 13

This issue features a look at the U.S. drug pricing system, attempts to solve physician burnout, and more.